Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharming has received US patent 8,071,532, covering a method of preventing, reducing or treating an ischemia and/or reperfusion injury by administering recombinant C1 inhibitor (Ruconest/ Rhucin).
Subscribe to our email newsletter
The broad claims in the patent provide protection until 2028.
The patent relates to a method of using recombinant C1 inhibitor (rhC1 INH), being produced either in cell cultures or in transgenic animals.
Recombinant C1 inhibitor showed to be therapeutically active in a time span of six hours and particularly useful for unforeseen occurrences of ischemic reperfusion such as stroke and myocardial infarction.
The other claims are directed to treatment during organ transplantations.
Pharming CEO Sijmen de Vries said the new patent further enhances the IP portfolio surrounding the company’s proprietary transgenic platform.